Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levonorgestrel is a synthetic second-generation progestogen that acts as a potent agonist of the progesterone receptor. It is widely utilized in various contraceptive formulations, including emergency contraceptive pills (ECPs), long-acting reversible contraceptives (LARCs) such as intrauterine systems (IUS), and combined oral contraceptive pills. As an emergency contraceptive, it primarily functions by delaying or inhibiting ovulation through the suppression of luteinizing hormone (LH) surges. It may also alter cervical mucus to impede sperm transport and, theoretically, inhibit implantation by altering the endometrium, although the latter mechanism is not the primary mode of action. The brand "Plan A," marketed by Afaxys Pharma, is a 1.5 mg single-dose oral tablet intended for use within 72 hours of unprotected intercourse or contraceptive failure.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levonorgestrel.